2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
26
Non-Muscle Invasive Bladder Neoplasms
13
Colorectal Neoplasms
3
Colonic Neoplasms
3
Recurrence
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Side Effect of Drug
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligospermia
1
Neuroblastoma
1
Fibrosis
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma in Situ
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
155
Dexamethasone
141
Rituximab
85
fludarabine
80
Lenalidomide
72
Cytarabine
70
Bortezomib
65
fludarabine phosphate
63
Gemcitabine
62
venetoclax
55
pomalidomide
53
Etoposide
53
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
BCG Vaccine
×
Clear all
NCT05037279
2026-03-20
EVER
Verity Pharmaceuticals Inc.
Phase 3
Recruiting
540 enrolled
NCT03664869
2021-04-01
FB10
Turku University Hospital
Phase 3
Unknown
300 enrolled